

Országos Onkológiai Intézet

Kísérletes farmakológiai Osztály

PUBLIKÁCIÓS LISTA

Dr. Tejeda Miguel

1. **Tejeda M.**, Gaál D., Szűcs I., Telekes A.: Avemar inhibits the growth of mouse and human xenograft mammary carcinoma comparable to endocrine treatment. Avemar Research Program, 183 p. 2008.
2. **M. Tejeda**, D. Gaál, L. Hullán, R. Schwab, O. Szokoloczi and Gy. Kéri: Continuous administration of the somatostatin structural derivative (TT-232) by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Anticancer Research, 28 (5): 2769-2774 p, 2008 (IF: 1.416).
3. **M. Tejeda**, D. Gaál, L. Hullán, R. Schwab, O. Szokoloczi, Gy. Kéri: Antitumor activity of the somatostatin structural derivative (TT-232) against mouse and human melanoma tumor models. Anticancer Research, 27:4015-4019, 2007 (IF: 1,416)
4. **M. Tejeda**, D. Gaál, I. Szűcs, Telekes A: Avemar inhibits the growth of mouse and human xenograft mammary carcinomas comparable to endocrine treatments. Journal of Clinical Oncology, 25(185):21132, 2007 (IF:13.598).
5. **M. Tejeda**, D. Gaál, L.Hullán, B. Hegymegi-Barakonyi and Gy.Kéri: Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Anticancer Research, 26:3477-3484, 2006. (IF: 1.416).
6. **M. Tejeda**, D. Gaál, L. Hullán, O. Csuka, R. Schwab, O. Szokoloczi and Gy. Kéri: A comparison of the tumor growth effect of intermittent and continuous administration of the somatostatin structural derivative (TT-232) in various human tumor models. Anticancer Research, 26:3011-3016, 2006. (IF:1.416)
7. **M. Tejeda**, D. Gaál, O. Csuka and Gy. Kéri: Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Research 25:325-330, 2005. (IF: 1.4.16)

8. **M. Tejeda**, D. Gaál, K. Barna, O. Csuka and Gy. Kéri: The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. *Anticancer Research*, 23:4061-4066, 2003. (IF: 1.416)
9. **Miguel Tejeda**, Dezső Gaál, Orsolya Csuka, Axel Ullrich, Richárd Schwab, Ákos Pap, Anikó Horváth, György Kéri: The antitumor effect of the somatostatin analogue TT-232 depends on the treatment regimen. *Cancer Detection and Prevention*, 27:155-162, 2003. (IF:1.324)
10. Richard Schwab, Sylvie Froidevaux, Sándor Paku, **Miguel Tejeda**, Béla Szende, Ákos Pap, Christoph Beglinger, Alex N. Eberle, György Kéri: Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumors. *Anticancer Research*, 21:71-76, 2001. (IF:1.416)
11. Kéri Gy., Érchegyi J., Horváth A., Mező I., Idei M., Vántus T., Balogh A., Vadász Zs., Bökönyi Gy., Teplán J., Csuka O., **M. Tejeda**, D.Gaál, Szegedi Zs., Szende B., C.Roze, H. Kalthoff and A. Ullrich: A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. *Medical Science, Proc.Natl.Acad.Sci, USA*, 93:12513-12518, 1996. (IF:10.000)
12. György Kéri, Judit Érchegyi, Anikó Horváth, Miklos Idei, István Teplán, Orsolya Csuka, **Miguel Tejeda**, Dezső Gaál, László Örfi, Zsolt Szegedi, Béla Szende: Induction of apoptosis and non-apoptotic programmed cell death by antitumor peptides and prptidomimetics. *Peptides*, 468-488, 1996. (IF: 2.038)
13. Kéri Gy., Érchegyi J., Horváth A., Mező I., Vántus T., Vadász Zs., Bökönyi Gy., Teplán I., Csuka O., **Tejeda M.**, Gaál D., Szegedi Zs., Szende B., Roce C., Kalthoff H.: TT-232 egy erős in vitro and in vivo antitumor mutató tumorszelektív szomatostatin analóg. *Biokémiai*, 4:155-166, 1995.